- Monoclonal Antibodies: What the Diagnostic Neuroradiologist Needs to Know
The therapeutic use of monoclonal antibodies is rapidly expanding for a variety of diseases. This review article describes commonly used monoclonal antibody-targeted therapeutic agents, their mechanism of action, clinical applications, and major adverse events with a focus on neurologic and neuroimaging manifestations. For example, immunostimulating anticancer mAbs can lead to proinflammatory conditions, while immunosuppressive medications can lead to activation of underlying opportunistic infections. Amyloid-segregating mAbs can lead to amyloid-related imaging abnormalities, and TNF-inhibiting mAbs have a higher incidence of demyelinating abnormalities.
- MR Imaging Appearance of Ruptured Rathke Cleft Cyst and Associated Bone Marrow Enhancement
This clinical case series of 7 patients illustrates the imaging finding of enhancing basisphenoid bone marrow below the sella in cases of ruptured RCC. The mucin leaking out of the ruptured RCC can trigger a cascade of surrounding inflammation, which manifests as abnormal bone marrow enhancement.
- Prevalence of Cochlear-Facial and Other Non-Superior Semicircular Canal Third Window Dehiscence on High-Resolution Temporal Bone CT
This study of 500 patients found the prevalence of non-SSCD on high-resolution CT in asymptomatic individuals to be 1.6% for CFD and 8.0% for JVD as compared with the rate in patients with audiologic or vestibular symptoms (2.9% for CFD and 7.8% for JVD). There was no statistically significant difference in the rates of radiologic findings between patients with reported symptoms suggestive of a possible third window syndrome and those without auditory or vestibular symptoms.
- DWI-Detected Ischemic Lesions after Endovascular Treatment for Cerebral Aneurysms: An Updated Systematic Review and Meta-analysis
This systematic review and meta-analysis found the incidence of new postprocedural DWI-detected ischemic lesions after endovascular treatment for intracranial aneurysms to be 47.0% (95% CI, 39.6%–55.8%), regardless of the endovascular procedure used. Studies have shown that almost half of these lesions are asymptomatic, and if small (<5 mm), these lesions have been shown to regress without negative effect on clinical outcome.
AJNR Awards, New Junior Editors, and more. Read the latest AJNR updates